FR3111560B1 - Procédé de détermination d’un champ d’irradiance ultraviolette et d’une durée optimale d’irradiation ultraviolette en vue de la désinfection d’une surface ou d’un objet - Google Patents

Procédé de détermination d’un champ d’irradiance ultraviolette et d’une durée optimale d’irradiation ultraviolette en vue de la désinfection d’une surface ou d’un objet Download PDF

Info

Publication number
FR3111560B1
FR3111560B1 FR2106376A FR2106376A FR3111560B1 FR 3111560 B1 FR3111560 B1 FR 3111560B1 FR 2106376 A FR2106376 A FR 2106376A FR 2106376 A FR2106376 A FR 2106376A FR 3111560 B1 FR3111560 B1 FR 3111560B1
Authority
FR
France
Prior art keywords
mesh
disinfection
irradiance
ultraviolet
ray
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2106376A
Other languages
English (en)
French (fr)
Other versions
FR3111560A1 (fr
Inventor
Thomas Zunino
Jules Gouret
Nawel Himdi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Zunino Innovation Conseil SAS
Original Assignee
Thomas Zunino Innovation Conseil SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Zunino Innovation Conseil SAS filed Critical Thomas Zunino Innovation Conseil SAS
Publication of FR3111560A1 publication Critical patent/FR3111560A1/fr
Application granted granted Critical
Publication of FR3111560B1 publication Critical patent/FR3111560B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/026—Measuring blood flow
    • A61B5/029—Measuring blood output from the heart, e.g. minute volume
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/103—Measuring devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
    • A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
    • A61B5/1124—Determining motor skills
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4842—Monitoring progression or stage of a disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T15/00—Three-dimensional [3D] image rendering
    • G06T15/06—Ray-tracing
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T15/00—Three-dimensional [3D] image rendering
    • G06T15/50—Lighting effects
    • G06T15/506—Illumination models
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Computer Graphics (AREA)
FR2106376A 2019-03-05 2021-06-16 Procédé de détermination d’un champ d’irradiance ultraviolette et d’une durée optimale d’irradiation ultraviolette en vue de la désinfection d’une surface ou d’un objet Active FR3111560B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962814252P 2019-03-05 2019-03-05
US201962942722P 2019-12-02 2019-12-02
PCT/IB2020/000186 WO2020178638A1 (en) 2019-03-05 2020-03-05 Methods of treating al amyloidosis
IBPCT/2020/000186 2020-06-17

Publications (2)

Publication Number Publication Date
FR3111560A1 FR3111560A1 (fr) 2021-12-24
FR3111560B1 true FR3111560B1 (fr) 2024-03-22

Family

ID=70476256

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2106376A Active FR3111560B1 (fr) 2019-03-05 2021-06-16 Procédé de détermination d’un champ d’irradiance ultraviolette et d’une durée optimale d’irradiation ultraviolette en vue de la désinfection d’une surface ou d’un objet

Country Status (17)

Country Link
US (3) US11692024B2 (cg-RX-API-DMAC7.html)
EP (2) EP3934689B1 (cg-RX-API-DMAC7.html)
JP (2) JP7619953B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220019656A (cg-RX-API-DMAC7.html)
CN (1) CN113811332A (cg-RX-API-DMAC7.html)
AU (1) AU2020231081A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021017550A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132780A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002318A1 (cg-RX-API-DMAC7.html)
FR (1) FR3111560B1 (cg-RX-API-DMAC7.html)
IL (1) IL286040A (cg-RX-API-DMAC7.html)
JO (1) JOP20210245A1 (cg-RX-API-DMAC7.html)
MA (1) MA55209A (cg-RX-API-DMAC7.html)
MX (1) MX2021010665A (cg-RX-API-DMAC7.html)
PH (1) PH12021552135A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109645QA (cg-RX-API-DMAC7.html)
WO (1) WO2020178638A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA55209A (fr) * 2019-03-05 2022-01-12 Prothena Biosciences Ltd Procédés de traitement de l'amylose al
WO2022056484A1 (en) * 2020-09-14 2022-03-17 Caelum Biosciences Method of treating amyloidosis
TW202332465A (zh) * 2021-01-29 2023-08-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法
KR20240133743A (ko) * 2022-01-11 2024-09-04 프로테나 바이오사이언시즈 리미티드 Al 아밀로이드증 치료 방법
TW202506727A (zh) * 2023-04-10 2025-02-16 美商麥迪紐有限責任公司 優化的cd3抗原結合結構域
TW202547553A (zh) * 2024-02-06 2025-12-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
MXPA06008700A (es) 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
WO2009086539A2 (en) 2007-12-28 2009-07-09 Elan Pharmaceuticals, Inc. Treatment and prophylaxis of amyloidosis
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
BR112014009866A2 (pt) * 2011-10-25 2018-09-04 Onclave Therapeutics Limited formulações de anticorpos e métodos
AU2012328524B2 (en) 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
US10213506B2 (en) 2014-08-26 2019-02-26 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
JP7027321B2 (ja) 2015-11-03 2022-03-01 ヤンセン バイオテツク,インコーポレーテツド 抗cd38抗体の皮下製剤及びその使用
RS63446B1 (sr) * 2016-06-30 2022-08-31 Prothena Biosciences Ltd Kompozicije za lečenje amiloidoze
US11382974B2 (en) * 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
CA3129890A1 (en) 2019-02-12 2020-08-20 Prothena Biosciences Limited Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells
MA55209A (fr) * 2019-03-05 2022-01-12 Prothena Biosciences Ltd Procédés de traitement de l'amylose al
TW202332465A (zh) 2021-01-29 2023-08-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法

Also Published As

Publication number Publication date
US20250188159A1 (en) 2025-06-12
KR20220019656A (ko) 2022-02-17
PH12021552135A1 (en) 2022-08-31
BR112021017550A2 (pt) 2021-11-09
EP3934689A1 (en) 2022-01-12
CN113811332A (zh) 2021-12-17
SG11202109645QA (en) 2021-10-28
JOP20210245A1 (ar) 2023-01-30
IL286040A (en) 2021-10-31
AU2020231081A1 (en) 2021-09-30
US12240894B2 (en) 2025-03-04
JP2025063135A (ja) 2025-04-15
MX2021010665A (es) 2021-12-10
WO2020178638A1 (en) 2020-09-10
EP3934689B1 (en) 2025-04-23
FR3111560A1 (fr) 2021-12-24
JP7619953B2 (ja) 2025-01-22
EP4582446A2 (en) 2025-07-09
CL2021002318A1 (es) 2022-05-06
US11692024B2 (en) 2023-07-04
MA55209A (fr) 2022-01-12
EP4582446A3 (en) 2025-08-13
CA3132780A1 (en) 2020-09-10
US20230331831A1 (en) 2023-10-19
JP2022522889A (ja) 2022-04-20
US20200308260A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
Kashan A new metaheuristic for optimization: optics inspired optimization (OIO)
US11275288B2 (en) Ballistic light modulations for image enhancement through fog
CN107003406B (zh) 检测区的离散化
EP3796068A4 (en) DEVICE FOR GENERATION OF AN OPTICAL PULSE PAIR, LIGHT DETECTION DEVICE AND LIGHT DETECTION METHOD
JP2014089180A5 (cg-RX-API-DMAC7.html)
MX2019013802A (es) Mejora de la seguridad para aplicaciones de uv mediante el seguimiento de los cambios en el desacoplamiento de uv.
BR112016029542A2 (pt) análise não invasiva de substância
EP3453479A8 (fr) Dispositif et procédé de marquage d'une lentille ophtalmique avec un laser pulsé de longueur d'onde et énergie par impulsion sélectionnées
WO2015038810A3 (en) User interface based on optical sensing and tracking of user's eye movement and position
FR3098683B1 (fr) Dispositif pour l’amélioration du rendement et de la qualité des végétaux par exposition aux UVs, procédé et utilisations associées
MX2016012804A (es) Dispositivo de procesamiento y metodo de procesamiento.
US20170363876A1 (en) Light irradiation device
US9995282B2 (en) Selectively perceptible wind turbine system
BRPI0513180A (pt) método para determinar uma posição de um feixe pulsado, e aparelho para alterar uma refração de um olho
FR3111560A1 (fr) Procédé de détermination d’un champ d’irradiance ultraviolette et d’une durée optimale d’irradiation ultraviolette en vue de la désinfection d’une surface ou d’un objet
SG10201803749SA (en) Reflectance detection method and reflectance detection apparatus
MX2017014474A (es) Metodo para determinar una composición química de una porción de escoria.
EP3837579A4 (en) GRID COLLIMATOR, BACKLIGHT SYSTEM AND METHOD USING A LIGHT REFLECTIVE LIGHT SOURCE
KR101919735B1 (ko) 발광 빔 각도 조절이 가능한 광학계, 라이다 센서 및 이의 발광 각도 조절 방법
Montalban et al. Bayesian inference of fog visibility from LiDAR point clouds and correlation with probabilities of detection
HK1253971A2 (zh) 在建筑物表面识别及确定预设点的方法
Trofimov et al. A mathematical model of optical bistability and the multiplicity of its solutions
FR3057974B1 (fr) Procede de gestion de taches
WO2021255348A1 (fr) Procédé de détermination dun champ dirradiance ultraviolette et dune durée optimale dirradiation ultraviolette en vue de la désinfection dune surface ou dun objet
BR0307097A (pt) Método e sistema de limpeza baseado em laser

Legal Events

Date Code Title Description
EXTE Extension to a french territory

Extension state: PF

PLFP Fee payment

Year of fee payment: 2

PLFP Fee payment

Year of fee payment: 3

PLSC Publication of the preliminary search report

Effective date: 20230728

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5